ClinicalTrials.gg
RecruitingNCT05802329DMEUpdated Jul 31, 2026

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

A Phase 1 interventional study of OCU200 in Center Involved Diabetic Macular Edema and Diabetic Macular Edema, sponsored by Ocugen. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Ocugen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
159th of 244
24 · median 45
Started
2024
with 8 others
Phase 1
43 of 276
3 open now
Primary completion
2026-07
later than 5 of 31 live
Registered
244th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 159th largest by planned enrollment of the 244 interventional ones that give a count, is one of 9 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 5 of the 31 other live ones, and was the 244th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema

Read the detailed description

This is a multicenter, open-label, dose ranging study with 4 cohorts in the dose-escalation portion of the study. An accelerated 3+3 design with parallel and sequential dosing will be used.

Under the escalation design, 12 subjects will be enrolled if there are no DLTs and up to 24 subjects under the condition that exactly 1 of the 3 subjects of every cohort if determined to have a DLT.

Each subject will receive a total of 2 intravitreal injections of OCU200 6 weeks apart.

The DSMB will review the sentinel subject 1 week safety data post dosing in every cohort of all 3 subjects.

Cohort 1: 3+3 participants will receive intravitreal injection of OCU200.

Cohort 2: 3+3 participants will receive intravitreal injection of OCU200.

Cohort 3: 3+3 participants will receive intravitreal injection of OCU200.

Cohort 4: 3+3 participants will receive intravitreal injection of OCU200.

03

Conditions studied

  • Center Involved Diabetic Macular Edema
  • Diabetic Macular Edema

Browse trials for

Keywords

  • anti-VEGF
  • Transferrin
  • Tumstatin
  • DME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Type 1 or Type 2 Diabetes Mellitus
  2. Decreased visual acuity attributable primarily to DME
  3. Central-involved DME with central retinal subfield thickness (CST) values, as assessed with spectral-domain optical coherence tomography (SD-OCT) of:

    1. ≥ 320 but ≤ 450µm if male or ≥ 305 but ≤ 435µm if female on Heidelberg Spectralis
    2. ≥ 305 but ≤ 435µm if male or ≥ 290 but ≤ 420µm if female on Zeiss Cirrus
  4. BCVA ≤ 78 and ≥ 24 letters on ETDRS chart
  5. Sufficient ocular media clarity, pupillary dilation and participant cooperation to permit acquisition of good quality retinal imaging
  6. No history of prior anti-VEGF injection or history of at least 2 consecutive intravitreal anti-VEGF injection (less than 7 weeks apart) with incomplete resolution of CST within 1 year.

Note: The last anti-VEGF injection must be administered at least six weeks (45 days) prior to the study treatment (Day 1) in the study eye.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any condition that prevent clear visualization of retina (e.g., significant cataract, vitreous hemorrhage)
  2. Uncontrolled hypertension
  3. Uncontrolled glaucoma
  4. Concurrent disease in the study eye, other than central-involved DME
  5. Intravitreal or periocular treatment within 3 months prior to the screening visit
  6. Any ocular surgery within 3 months prior to the screening visit in the study eye
  7. Uncontrolled/poorly controlled diabetes ( (HbA1c) ≥ 10%)
  8. History of retinal detachment in the study eye or other retinal vascular disease in the study eye
  9. Focal or pan-retinal laser photocoagulation in the study eye within 3 months prior to the screening visit
  10. Presence of any inherited retinal disease or history of proliferative diabetic retinopathy
  11. History of Renal disease including stage 3b or worse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    3+3 participants will receive intravitreal injection of OCU200 (0.5 mg/mL concentration).

    Drug: OCU200

  • Experimental
    Cohort 2

    3+3 participants will receive intravitreal injection of OCU200 (1 mg/ML concentration).

    Drug: OCU200

  • Experimental
    Cohort 3

    3+3 participants will receive intravitreal injection of OCU200 (2 mg/mL concentration).

    Drug: OCU200

  • Experimental
    Cohort 4

    3+3 participants will receive intravitreal injection of OCU200 (5 mg/mL concentration).

    Drug: OCU200

Interventions

  • DrugOCU200

    Intravitreal Injection

06

What researchers measure

Primary outcomes

  1. Study Drug-related adverse events (SDAE)

    Counts, frequencies and percentages of SDAEs.

    Time frame: 24 weeks

  2. Treatment-emergent adverse events (TEAEs)

    Counts, frequencies and percentages TEAEs.

    Time frame: 24 weeks

  3. Serious adverse events (SAEs)

    Counts, frequencies and percentages of SAEs.

    Time frame: 24 weeks

Secondary outcomes

  1. Best-corrected visual acuity (BCVA)

    Measured as the ETDRS letter score on the EVA tester or E-ETDRS charts.

    Time frame: 24 Weeks (Changes from baseline)

  2. Intraocular pressure (IOP)

    IOP measurement by applanation or rebound tonometry.

    Time frame: 24 weeks(Changes from baseline)

  3. Color fundus photography

    Color fundus photographs will be taken to evaluate retinal anatomy and grade diabetic retinopathy severity scale (DRSS).

    Time frame: 24 Weeks(Changes from baseline)

  4. Spectral Domain Optical Coherence Tomography (SD-OCT)

    SD-OCT will be utilized to assess retinal thickness. OCT images and scans will be transmitted to a central reading center for independent analysis.

    Time frame: 24 Weeks(Changes from baseline)

  5. Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA)

    SD-OCTA will be utilized to assess retinal vasculature and images will be transmitted to a central reader for independent analysis.

    Time frame: 24 weeks (Changes from baseline)

  6. Wide-field Fluorescein Angiography (wf-FA)

    wf-FA will be conducted at screening and EOS visits to assess central and peripheral vasculature.

    Time frame: 24 weeks (Changes from baseline)

Other outcomes

  1. Improvement of diabetic retinopathy severity scale (DRSS)

    Proportion of participants with ≥ 2-step improvement of diabetic retinopathy severity scale (DRSS)

    Time frame: 24 weeks

  2. Change from baseline in BCVA letters.

    Dose response as assessed by mean change from baseline in BCVA letters and mean number of injections by study visit

    Time frame: 24 weeks

  3. Reduction of CST

    The proportion of participants having a ≥ 10% reduction of CST at Week 13 and Week 19

    Time frame: 24 Weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2026, 30 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 6, 2023
StartActual
Jan 13, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05802329
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
Jan 13, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Jul 31, 2026

Study contacts

Roshan A George, MD, MPH
Contact
roshan.george@ocugen.com
845-664-1505
Oscar Cuzzani, MD, PhD
Contact
Oscar.Cuzzani@ocugen.com
Jennifer Henrick, RN, MS
study director · Ocugen
Mohamed Genead, MD
study chair · Ocugen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion